Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,612 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Kyoto Prognostic Index for patients with diffuse large B-cell lymphoma in the rituximab era.
Kobayashi T, Kuroda J, Yokota I, Tanba K, Fujino T, Kuwahara S, Isa R, Yamaguchi J, Kawata E, Akaogi T, Uchiyama H, Kaneko H, Uoshima N, Kobayashi Y, Teramukai S, Taniwaki M. Kobayashi T, et al. Among authors: kobayashi y. Blood Cancer J. 2016 Jan 15;6(1):e383. doi: 10.1038/bcj.2015.111. Blood Cancer J. 2016. PMID: 26771809 Free PMC article. No abstract available.
Clinical manifestation and prognostic factors of 32 Japanese patients with autoimmune disease-associated diffuse large B-cell lymphoma.
Maegawa S, Kuroda J, Kobayashi T, Fuchida S, Kawata E, Kamitsuji Y, Tsutsumi Y, Iwai T, Nakao M, Kaneko H, Uoshima N, Shimazaki C, Kobayashi Y, Horiike S, Yamamoto A, Kawahito Y, Taniwaki M. Maegawa S, et al. Among authors: kobayashi y, kobayashi t. Leuk Lymphoma. 2015 Mar;56(3):785-8. doi: 10.3109/10428194.2014.928936. Epub 2014 Jun 25. Leuk Lymphoma. 2015. PMID: 24884317 No abstract available.
Prognostic impact of a past or synchronous second cancer in diffuse large B cell lymphoma.
Tanba K, Chinen Y, Uchiyama H, Uoshima N, Shimura K, Fuchida S, Kiyota M, Nakao M, Shimura Y, Kobayashi T, Horiike S, Wada K, Shimazaki C, Kaneko H, Kobayashi Y, Taniwaki M, Kuroda J. Tanba K, et al. Among authors: kobayashi y, kobayashi t. Blood Cancer J. 2018 Jan 25;8(1):1. doi: 10.1038/s41408-017-0043-6. Blood Cancer J. 2018. PMID: 29367648 Free PMC article. Clinical Trial. No abstract available.
Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study.
Matsumoto Y, Kobayashi T, Shimura Y, Kawata E, Nagoshi H, Ohshiro M, Sugitani M, Shimura K, Iwai T, Fuchida SI, Yoshida M, Kiyota M, Mizutani S, Chinen Y, Takimoto-Shimomura T, Nakao M, Kaneko H, Uchiyama H, Uoshima N, Nishigaki H, Kobayashi Y, Horiike S, Shimazaki C, Taniwaki M, Kuroda J; Kyoto Clinical Hematology Study Group (KOTOSG). Matsumoto Y, et al. Among authors: kobayashi y, kobayashi t. Int J Hematol. 2019 Jul;110(1):77-85. doi: 10.1007/s12185-019-02650-w. Epub 2019 May 24. Int J Hematol. 2019. PMID: 31127456 Clinical Trial.
Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphoma.
Chinen Y, Tanba K, Takagi R, Uchiyama H, Uoshima N, Shimura K, Fuchida SI, Kiyota M, Nakao M, Tsukamoto T, Shimura Y, Kobayashi T, Horiike S, Wada K, Shimazaki C, Kaneko H, Kobayashi Y, Taniwaki M, Yokota I, Kuroda J; Kyoto Clinical Hematology Study Group investigators. Chinen Y, et al. Among authors: kobayashi y, kobayashi t. Leuk Lymphoma. 2020 Dec;61(14):3378-3386. doi: 10.1080/10428194.2020.1811862. Epub 2020 Aug 27. Leuk Lymphoma. 2020. PMID: 32852234
Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: the collaborative study at six institutes in Kyoto and Osaka.
Kobayashi T, Kuroda J, Shimura K, Akaogi T, Kawata E, Kiyota M, Tanaka T, Kamitsuji Y, Murakami S, Hatsuse M, Okano A, Iwai T, Ueda S, Koshida M, Uchiyama H, Matsumoto Y, Kaneko H, Uoshima N, Ueda Y, Kobayashi Y, Shimazaki C, Horiike S, Taniwaki M. Kobayashi T, et al. Among authors: kobayashi y. Int J Hematol. 2010 Nov;92(4):579-86. doi: 10.1007/s12185-010-0696-4. Epub 2010 Oct 7. Int J Hematol. 2010. PMID: 20924731
ADAMTS-13 activity can predict the outcome of disseminated intravascular coagulation in hematologic malignancies treated with recombinant human soluble thrombomodulin.
Ohshiro M, Kuroda J, Kobayashi Y, Akaogi T, Kawata E, Uoshima N, Kamitsuji Y, Kaneko H, Shimura K, Shimazaki C, Murakami S, Hatsuse M, Okano A, Kobayashi T, Uchiyama H, Matsumoto Y, Horiike S, Taniwaki M. Ohshiro M, et al. Among authors: kobayashi y, kobayashi t. Am J Hematol. 2012 Jan;87(1):116-9. doi: 10.1002/ajh.22185. Epub 2011 Oct 12. Am J Hematol. 2012. PMID: 21989545 Free article. Clinical Trial. No abstract available.
10,612 results
You have reached the last available page of results. Please see the User Guide for more information.